These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25299869)

  • 1. Longevity loss among cured tuberculosis patients and the potential value of prevention.
    Hoger S; Lykens K; Beavers SF; Katz D; Miller TL
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1347-52. PubMed ID: 25299869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regarding the effect of cured tuberculosis disease on longevity.
    Lalli M; Houben R; Churchyard G; White RG
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):367. PubMed ID: 25692935
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality hazard and survival after tuberculosis treatment.
    Miller TL; Wilson FA; Pang JW; Beavers S; Hoger S; Sharnprapai S; Pagaoa M; Katz DJ; Weis SE
    Am J Public Health; 2015 May; 105(5):930-7. PubMed ID: 25790407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In reply.
    Hoger S; Lykens K; Beavers S; Katz D; Miller T
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):367-8. PubMed ID: 25692934
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States.
    Lee-Rodriguez C; Wada PY; Hung YY; Skarbinski J
    JAMA Netw Open; 2020 Sep; 3(9):e2014481. PubMed ID: 32965497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study.
    Araújo NCN; Cruz CMS; Arriaga MB; Cubillos-Angulo JM; Rocha MS; Silveira-Mattos PS; Matos GM; Marques IMB; Espirito Santo ICP; Almeida LL; Andrade CM; Souza LA; Netto EM; Andrade BB
    Int J Infect Dis; 2020 Apr; 93():277-283. PubMed ID: 32081776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.
    Getahun B; Ameni G; Biadgilign S; Medhin G
    BMC Infect Dis; 2011 May; 11():127. PubMed ID: 21575187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan.
    Huang SF; Chen MH; Wang FD; Tsai CY; Fung CP; Su WJ
    J Microbiol Immunol Infect; 2018 Dec; 51(6):784-793. PubMed ID: 28739436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response.
    Warsinske HC; Rao AM; Moreira FMF; Santos PCP; Liu AB; Scott M; Malherbe ST; Ronacher K; Walzl G; Winter J; Sweeney TE; Croda J; Andrews JR; Khatri P
    JAMA Netw Open; 2018 Oct; 1(6):e183779. PubMed ID: 30646264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
    Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
    AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of treatment of latent tuberculosis infection in individual patients.
    Dobler CC; Martin A; Marks GB
    Eur Respir J; 2015 Nov; 46(5):1397-406. PubMed ID: 26405292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data.
    Kawatsu L; Uchimura K; Ohkado A
    BMC Infect Dis; 2021 Jan; 21(1):42. PubMed ID: 33422003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
    Kwon M; Sung M; Kwon YJ; Song YG; Lee SW; Park MC; Park YB; Lee SK; Song JJ
    J Clin Rheumatol; 2014 Mar; 20(2):68-73. PubMed ID: 24561408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of unsuccessful treatment outcomes and mortality among tuberculosis patients in Malaysia: A registry-based cohort study.
    Tok PSK; Liew SM; Wong LP; Razali A; Loganathan T; Chinna K; Ismail N; Kadir NA
    PLoS One; 2020; 15(4):e0231986. PubMed ID: 32320443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon.
    Tanue EA; Nsagha DS; Njamen TN; Assob NJC
    PLoS One; 2019; 14(7):e0218800. PubMed ID: 31361755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review.
    Clifford V; He Y; Zufferey C; Connell T; Curtis N
    Tuberculosis (Edinb); 2015 Dec; 95(6):639-650. PubMed ID: 26515270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands.
    Gafar F; Van't Boveneind-Vrubleuskaya N; Akkerman OW; Wilffert B; Alffenaar JC
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31515410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region.
    Chung CY; Li KKW
    Int Ophthalmol; 2018 Dec; 38(6):2273-2282. PubMed ID: 28948453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.
    Sadatsafavi M; Marra C; Marra F; Moran O; FitzGerald JM; Lynd L
    Value Health; 2013; 16(1):66-75. PubMed ID: 23337217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.